|
 | Up a level |
Abbott, KL and Chaudhury, CS and Chandran, A and Vishveshwara, S and Dvorak, Z and Jiskrova, E and Poulikova, K and Vyhlidalova, B and Mani, S and Pondugula, SR (2019) Belinostat, at its clinically relevant concentrations, inhibits rifampicin-induced CYP3A4 and MDR1 gene expressions. In: Molecular Pharmacology, 95 (3). pp. 324-334.
